Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

Updates in ALL: Incorporating Immunotherapy in Frontline Management

Talha Badar

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Blinatumomab in First-Line ALL - Safety, Efficacy, and Experience

Salman Fazal

Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…

UChicago Medicine

A. Cooper

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

Incorporating Blinatumomab and Inotuzumab Into 1L ALL Treatment

MyCancerHaven

R. Vij, N. Short

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

The Importance of MRD in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

Treating Adults With Newly Diagnosed ALL

MyCancerHaven

R. Vij, A. Patel

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin